Summary & Overview
HCPCS J1806: Esmolol Hydrochloride Injection, 10 mg
HCPCS Level II code J1806 denotes a 10 mg vial injection of esmolol hydrochloride intended for critical care use and is designated as not therapeutically equivalent to J1805. This code is significant nationally because esmolol is a short-acting, intravenous beta-blocker commonly used in acute inpatient and intensive care settings for rapid rate control and hemodynamic stabilization. Accurate coding ensures correct billing for high-acuity medication administrations and supports appropriate utilization tracking for critical care therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for J1806, expected sites of service, and the practical implications for facility billing. The publication outlines typical benchmarks and reimbursement considerations, identifies policy and coverage drivers affecting payment for critical care injectable medications, and summarizes coding nuances tied to therapeutic equivalence distinctions. Where payer-specific coverage rules differ, high-level comparisons are provided to guide billing staff and policy analysts in understanding national payer behaviors. Data not available in the input will be noted in relevant sections.
Billing Code Overview
HCPCS Level II code J1806 represents an injection of esmolol hydrochloride, specified as "(wg critical care), not therapeutically equivalent to j1805, 10 mg." The service type is an intravenous injectable medication administration for acute or critical care settings. The typical site of service is inpatient hospital units and critical care settings where short-acting beta-blockade with esmolol is used for rate control or hemodynamic management.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient in the intensive care unit develops acute supraventricular tachycardia with rapid ventricular response and hemodynamic instability not responsive to initial vagal maneuvers and rate-controlling oral agents. The clinical team elects to initiate intravenous esmolol therapy for short-acting beta blockade to rapidly control heart rate while assessing for reversible causes and preparing for further interventions. A pharmacy or critical care nurse reconstitutes and prepares the J1806 product (esmolol hydrochloride) in the appropriate concentration; the medication is administered via bolus and continuous infusion through a monitored infusion pump with continuous ECG, blood pressure, and oxygen saturation monitoring. Dosing is titrated based on heart rate and blood pressure, and documentation includes indication, dose, route, start/stop times, infusion rates, and patient response. Typical sites of service include the emergency department, intensive care unit, and perioperative critical care settings where short-acting intravenous beta blockade is required for acute rate control.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedural modifier indicating standard service | Use when no special modifier applies and billing requires the default service indicator |